Registration number:
CGSkin Limited
for the Year Ended 30 June 2024
CGSkin Limited
(Registration number: 08102822)
Balance Sheet as at 30 June 2024
Note |
2024 |
2023 |
|
Fixed assets |
|||
Intangible assets |
|
|
|
Current assets |
|||
Debtors |
|
|
|
Cash at bank and in hand |
|
|
|
|
|
||
Creditors: Amounts falling due within one year |
( |
( |
|
Net current liabilities |
( |
( |
|
Net liabilities |
( |
( |
|
Capital and reserves |
|||
Called up share capital |
42,443 |
42,443 |
|
Share premium reserve |
44,250 |
44,250 |
|
Retained earnings |
(186,826) |
(152,567) |
|
Shareholders' deficit |
(100,133) |
(65,874) |
For the financial year ending 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
• |
|
• |
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. |
Approved and authorised by the
|
|
CGSkin Limited
Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024
General information |
The company is a private company limited by share capital, incorporated in England & Wales.
The address of its registered office is:
United Kingdom
These financial statements were authorised for issue by the
Accounting policies |
Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
Statement of compliance
These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).
Basis of preparation
These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.
Development costs
Costs relating to product development are recognised as an intangible asset in order to evenly match them against anticipated future revenue streams. Development costs are only capitalised if:
a) it is probable that the expected future economic benefits that are attributable to the development costs will flow to the company, and
b) costs can be measured reliably
Research costs are written off in the period in which they are incurred.
Cash and cash equivalents
Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.
Share capital
Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.
CGSkin Limited
Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024
Staff numbers |
The average number of persons employed by the company (including directors) during the year, was
Intangible assets |
Other intangible assets |
Total |
|
Cost or valuation |
||
At 1 July 2023 |
|
|
At 30 June 2024 |
|
|
Amortisation |
||
Carrying amount |
||
At 30 June 2024 |
|
|
At 30 June 2023 |
|
|
Debtors |
2024 |
2023 |
|
VAT Control account |
7 |
7 |
|
|
Creditors |
Creditors: amounts falling due within one year
2024 |
2023 |
|
Due within one year |
||
Trade creditors |
77 |
56 |
Other related parties |
108,017 |
108,017 |
Accruals and deferred income |
|
|
Other creditors |
|
- |
|
|
CGSkin Limited
Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024
Share capital |
Allotted, called up and fully paid shares
2024 |
2023 |
|||
No. |
£ |
No. |
£ |
|
|
|
10,000 |
|
10,000 |
|
|
32,443 |
|
32,443 |
|
|
|
|
Related party transactions |
Loans from related parties
2024 |
Key management |
Total |
At start of period |
|
|
At end of period |
|
|
|
2023 |
Key management |
Total |
At start of period |
|
|
At end of period |
|
|
|
Terms of loans from related parties
Non adjusting events after the financial period |
|